Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... in attacking cancer cells in patients with leukemia, MDS, lymphoma, Hodgkin disease, or MM, after they have received an ... or are not in a complete response at day 28 can receive secondary therapy. Drug: Methylprednisolone 1.6 mg/kg per day by vein ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  2. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... period, and then resume prior medications. Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.

  3. Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

    ... (KPT-330) that we can give to patients with leukemia or MDS, when it is combined with fludarabine and cytarabine. The goal of the ... leukemia (MPAL) and myelodysplastic syndrome (MDS). SECONDARY OBJECTIVES: To characterize the pharmacokinetics of selinexor, ...

    Clinical Trial last updated 04/28/2016 - 9:48am.

  4. Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    ... acute myeloid leukemia (AML) ormyelodysplastic syndrome (MDS). The purpose of this study is to test the safety of panobinostat and ... patients with relapsed or refractory AML or MDS. SECONDARY OBJECTIVES: Characterize the pharmacokinetics of panobinostat ...

    Clinical Trial last updated 04/29/2016 - 10:11am.

  5. T-cell Depleted Alternative Donor Transplantation

    ... an alternative (unrelated and mismatched related) donor. The secondary objectives include evaluation of engraftment , immune ... myelodysplastic syndromes (MDS) Phase:  ...

    Clinical Trial last updated 04/29/2016 - 3:38pm.

  6. RIC Transplant Using Haplo Donors

    ... estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, ... myelodysplastic syndromes (MDS) Associated Drug(s):  ...

    Clinical Trial last updated 04/29/2016 - 10:52am.

  7. GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t(8;21), t(15;17), inv 16). Secondary AML ALL/LL in 1st remission with clinical or molecular features ...

    Clinical Trial last updated 04/29/2016 - 12:40pm.

  8. Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

    ... myelodysplastic syndromes (MDS) Phase:  ... > 50 cc/min SGPT and SGOT < 2.5 x ULN, unless elevated secondary to disease. Total bilirubin < 2 x ULN (patients with ...

    Clinical Trial last updated 05/09/2016 - 3:58pm.

  9. HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st remission AML in 1st relapse or > than or = to 2nd ...

    Clinical Trial last updated 04/29/2016 - 3:18pm.

  10. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st remission AML in 1st relapse or > 2nd remission ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.